Phase 1 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older, of any gender
• People diagnosed with acute myeloid leukaemia (AML) that has come back or stopped responding to previous treatment
• People with a general health and activity level rated between 0 and 2 on a standard medical scale (meaning able to carry out at least some daily activities)
• People whose doctors estimate they have a life expectancy of at least 3 months
• People with adequate bone marrow function and sufficiently healthy organ function
• People who are able to understand the study's purpose and risks, and are willing to sign a consent form

Who may not be able to join:

• People who have received cancer treatments (such as chemotherapy, immunotherapy, targeted therapy, radiation, or hormone therapy) within 2 weeks or 5 half-lives of the treatment — whichever is the longer period — before the trial starts
• People who have taken part in another clinical trial and received an experimental treatment within 4 weeks before the trial starts
• People who have had major surgery within 4 weeks before the trial starts, or who are expected to need surgery during the trial
• People whose AML is a specific subtype, including acute promyelocytic leukaemia, AML arising from a blast crisis of chronic myelogenous leukaemia, or AML that has spread to the central nervous system
• People with a current or previous separate cancer diagnosis, unless it was a fully cured non-invasive skin cancer, or another cancer that was fully cured more than 5 years ago with no recurrence (confirm with trial site)
• People with a history of severe heart or brain blood vessel disease
• People who have taken certain strong medications known to significantly affect how the body processes drugs (strong CYP3A4 or P-gp inhibitors or inducers) within 7 days before the trial starts
• People who have received a live or weakened live vaccine within 4 weeks before the trial starts, or who plan to receive one during the trial
• People who still have unresolved significant side effects (grade 2 or higher) from previous AML treatment, other than hair loss or other effects the doctor considers tolerable
• People who have previously had an allogeneic (donor) stem cell transplant, or who have had an autologous (own cells) stem cell transplant within 3 months before the trial starts
• People who are unable to swallow tablets, or who have conditions that seriously affect the absorption of medicines through the digestive system
• People with infections that are not under control, as judged by the treating doctor
• People with a known infection of hepatitis B, hepatitis C, HIV, or syphilis
• People with known alcohol or drug dependence
• People with mental health conditions or who are unlikely to be able to follow the trial requirements
• People with a history of severe allergic reactions to any medicine or food
• Women who are pregnant or breastfeeding, and people of any gender (or their partners) who are planning a pregnancy and are not willing to use adequate contraception throughout the trial and for up to 3 months after the last dose
• People considered unsuitable for the trial for other reasons, as judged by the treating doctor

Important: Always verify eligibility with the trial site directly before applying.